Open AccessLong Covid: A Review on Cardiovascular Disease (CVD) in Post-Acute Sequalae of SARS-CoV-2 Infection (PASC)
Author(s) -
I. Sabrina,
Nany Hairunisa,
Emad͏͏͏͏͏͏͏͏͏͏͏͏͏͏͏͏͏͏͏ Yousif
Publication year - 2021
Publication title -
biointerface research in applied chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.216
H-Index - 11
ISSN - 2069-5837
DOI - 10.33263/briac123.39893995
Subject(s) - medicine , asymptomatic , covid-19 , pandemic , disease , chest pain , intensive care medicine , coronavirus , infectious disease (medical specialty)
Coronavirus disease 2019 (COVID-19) caused by the virus SARS-CoV-2 was declared a pandemic by the World Health Organization (WHO) in March 2020. The clinical spectrum of COVID-19 can range from asymptomatic to severe symptoms and even death. Recent studies show that a growing number of patients with COVID-19 will experience prolonged symptoms (Post-Acute Sequalae of SARS-CoV-2), which now days known as “Long Covid”. A team of researchers from Italy reported that nearly 9 in 10 patients discharged were still experiencing at least one symptom 60 days after infection. Symptoms reported are fatigue, dyspnea, joint pain, chest pain, and other uncommon symptoms. Through ACE2 surface receptor, SARS-CoV-2 has been linked to cardiovascular events. As PASC symptoms vary widely, cardiovascular sequelae need to be considered through lifetime management. Therefore, this review aims to summarize an update of the long covid effect on Cardiovascular Disease (CVD), the impacts, and Post-Acute Sequalae of SARS-CoV-2 Infection (PASC) management.